Trial record 1 of 1 for:
Bosutinib for ADPKD
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01233869
First received: October 28, 2010
Last updated: February 10, 2016
Last verified: February 2016
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or equal to 60 mL/min/1.73m2.
| Condition | Intervention | Phase |
|---|---|---|
|
Polycystic Kidney, Autosomal Dominant |
Drug: Bosutinib Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Resource links provided by NLM:
Genetics Home Reference related topics:
polycystic kidney disease
MedlinePlus related topics:
Kidney Diseases
Drug Information available for:
Bosutinib
U.S. FDA Resources
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Change From Baseline (CFB) in Total Kidney Volume (TKV) at Month 25 [ Time Frame: Baseline and Month 25 (end of Initial Treatment Period Visit [ITPV]) ] [ Designated as safety issue: No ]TKV was measured by centrally evaluated Magnetic Resonance Imaging (MRI).
Secondary Outcome Measures:
- Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 24, 25 and Early Termination [ Time Frame: Baseline, Month 12, Month 24, Month 25 (end of ITPV), and early termination ] [ Designated as safety issue: No ]eGFR was centrally evaluated. Glomerular filtration rate (GFR) is an index of kidney function that describes the flow of filtered fluid through the kidney. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate eGFR. Month 25 is the end of the ITPV.
- Time to First Occurrence or Worsening of Hypertension [ Time Frame: Baseline up to Month 25 (end of ITPV) ] [ Designated as safety issue: No ]The time to first occurrence or worsening of hypertension was observed (defined as the need for increased dose of or need for additional anti-hypertensive medication). The numbers presented correspond to the very first occurrence or worsening of hypertension in that treatment group.
- Time to First Occurrence or Worsening of Back and/or Flank Pain [ Time Frame: Baseline up to Month 25 (end of ITPV) ] [ Designated as safety issue: No ]The time to first occurrence or worsening of back and/or flank pain was observed (defined as initial onset of polycystic kidney disease [PKD]-related chronic back and/or flank pain; initiation of pain medication treatment for PKD-related chronic back and/or flank pain; addition of a pain medicine for treatment of PKD-related chronic back and/or flank pain; increase in dose of pain medication for treatment of PKD-related chronic back and/or flank pain). The numbers presented correspond to the very first occurrence or worsening of back and/or flank pain in that treatment group.
- Time to First Occurrence of Gross Hematuria [ Time Frame: Baseline up to Month 25 (end of ITPV) ] [ Designated as safety issue: No ]Gross hematuria is the presence of blood in the urine (defined as pink, red, or cola-colored urine due to the presence of red blood cells). The numbers presented correspond to the very first occurrence of gross hematuria in that treatment group.
- Time to First Occurrence of Proteinuria [ Time Frame: Baseline up to Month 25 (end of ITPV) ] [ Designated as safety issue: No ]Proteinuria is the presence of an excess of serum proteins in the urine, which may be an early sign of kidney disease. The numbers presented correspond to the very first occurrence of proteinuria in that treatment group.
- Time to First Occurrence of End-Stage Renal Disease (ESRD) Requiring Dialysis >=56 Days [ Time Frame: Baseline up to Month 25 (end of ITPV) ] [ Designated as safety issue: No ]ESRD is when the kidneys permanently fail to work at a level needed for daily life. No participants developed ESRD during the treatment period, therefore the analysis of the onset of ESRD requiring ≥56 days of dialysis was not performed.
- Number of Participants With High Blood Urea Nitrogen (BUN) Levels [ Time Frame: Day 15, Months 6, 12, 18, 24, and 25 (end of ITPV) ] [ Designated as safety issue: No ]A BUN test can reveal how well the kidneys are working by measuring the amount of urea nitrogen in the blood. A high BUN level (>1.3 times the upper limit of normal) may suggest that the kidneys are not working properly. Month 25 is the end of the ITPV.
- Number of Participants With High Serum Creatinine (SCr) Levels [ Time Frame: Day 15, Months 6, 12, 18, 24, and 25 (end of ITPV) ] [ Designated as safety issue: No ]A SCr test can reveal how well the kidneys are working by measuring the amount of urea nitrogen in the blood. A high SCr level (>1.3 times the upper limit of normal) may suggest that the kidneys are not working properly. Month 25 is the end of the ITPV.
- Maximum Observed Plasma Concentration (Cmax) of Bosutinib [ Time Frame: Day 1 (pre-dose and 1, 3, 5 and 24 hours post-dose), Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bosutinib [ Time Frame: Day 1 (pre-dose and 1, 3, 5 and 24 hours post-dose), Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]
- Area Under the Concentration-Time Profile From Time 0 to the Dosing Interval (AUCtau) of Bosutinib [ Time Frame: Day 1 (pre-dose and 1, 3, 5 and 24 hours post-dose), Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]Area under the concentration-time profile from time 0 to time tau, the dosing interval, where tau=24 hours.
- Lowest Concentration Observed During the Dosing Interval (Cmin) of Bosutinib [ Time Frame: Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]
- Apparent Oral Clearance (CL/F) of Bosutinib [ Time Frame: Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
- Apparent Volume of Distribution (Vz/F) of Bosutinib [ Time Frame: Day 1 (pre-dose and 1, 3, 5 and 24 hours post-dose), Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
- Terminal Elimination Half-Life (t1/2) of Bosutinib [ Time Frame: Day 1 (pre-dose and 1, 3, 5 and 24 hours post-dose), Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]t1/2 is the time measured for the plasma concentration to decrease by one half.
- Observed Accumulation Ratio (Rac) of Bosutinib [ Time Frame: Day 15 (pre-dose and 1, 2, 3, 4, 6, 8 and 24 hours post-dose) ] [ Designated as safety issue: No ]Observed accumulation ratio (Rac) was calculated as AUC from time 0 to 24 hours (Day 15) divided by AUC from time 0 to 24 hours (Day 1).
- Change From Baseline in Kidney Disease Quality of Life (KDQoL)-36 Scale Scores at Month 25 [ Time Frame: Baseline and end of ITPV (Month 25) ] [ Designated as safety issue: No ]The KDQoL-36 is a 36-item questionnaire on kidney disease-specific measure of patient-reported quality of life with 5 subscales: physical and mental functioning (items 1-12); burden of kidney disease subscale (items 13-16); symptoms and problems (items 17-28); effects of kidney disease on daily life subscale (items 29-36). The raw scores are transformed linearly to a range of 0 to 100, with higher scores indicating better quality of life.
Other Outcome Measures:
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 30 days after last study drug administration ] [ Designated as safety issue: Yes ]An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
- Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern [ Time Frame: Baseline up to 30 days after last study drug administration ] [ Designated as safety issue: Yes ]The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, RBC morphology, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, and total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy [if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase]); others (coagulation panel, circulating immune complex, and complement activation).
- Number of Participants With Potentially Clinically Significant Vital Signs Findings [ Time Frame: Baseline up to 30 days after last study drug administration ] [ Designated as safety issue: Yes ]Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: supine/sitting pulse rate <40 or >120 beats per minute (bpm), standing pulse rate <40 or >140 bpm; systolic blood pressure (SBP) of >=30 millimeters of mercury (mm Hg) change from baseline in same posture or SBP <90 mm Hg, diastolic blood pressure (DBP) >=20 mmHg change from baseline in same posture or DBP <50 mm Hg.
- Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings [ Time Frame: Baseline up to 30 days after last study drug administration ] [ Designated as safety issue: Yes ]ECGs were centrally evaluated. ECG parameters included PR interval, QRS interval, and corrected QT interval using Fridericia's formula (QTcF). Criteria for ECG changes meeting potential clinical concern included: PR interval greater than or equal to (≥)300 milliseconds (msec) or ≥25% increase when baseline is greater than (>)200 msec and ≥50% increase when baseline is less than or equal to (≤)200 msec; QRS interval ≥200 msec or ≥25%/50% increase from baseline; and QTcF ≥450 msec or ≥30 msec increase.
| Enrollment: | 172 |
| Study Start Date: | December 2010 |
| Study Completion Date: | August 2014 |
| Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Cohort A |
Drug: Bosutinib
Once daily oral dose of 200 mg of bosutinib
|
| Experimental: Cohort B |
Drug: Bosutinib
Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
|
| Placebo Comparator: Cohort C |
Drug: Placebo
Once daily oral dose of placebo
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males and females, 18 to 50 years old at the time of consent.
- Documented diagnosis of ADPKD (PKD-1 or PKD-2 genotypes allowed).
- Total kidney volume ≥ 750 cc, as measured by centrally evaluated MRI.
Exclusion Criteria:
- eGFR < 60 mL/min/1.73m2.
- Uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg).
- Any previous exposure to the bosutinib test article or receipt of other polycystic kidney disease (PKD) therapies.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01233869
Hide Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01233869
Hide Study Locations
Locations
| United States, Arizona | |
| Southwest Kidney Institute, PLC | |
| Phoenix, Arizona, United States, 85004 | |
| Southwest Clinical Research Institute, LLC | |
| Tempe, Arizona, United States, 85284 | |
| Southwest Kidney Institute, PLC | |
| Tempe, Arizona, United States, 85284 | |
| United States, California | |
| Capital Nephrology Clinical Research | |
| Sacramento, California, United States, 95825 | |
| United States, Idaho | |
| Boise Kidney & Hypertension Institute, PLLC | |
| Caldwell, Idaho, United States, 83605 | |
| Boise Kidney & Hypertension Institute, PLLC | |
| Meridian, Idaho, United States, 83642 | |
| United States, Louisiana | |
| Renal Associates of Baton Rouge | |
| Baton Rouge, Louisiana, United States, 70808 | |
| United States, Massachusetts | |
| Tufts Medical Center | |
| Boston, Massachusetts, United States, 02111 | |
| United States, Missouri | |
| Washington University School of Medicine | |
| St. Louis, Missouri, United States, 63110 | |
| Washington University | |
| St. Louis, Missouri, United States, 63110 | |
| United States, New York | |
| New York University - HHC CTSI Clinical Research Center | |
| New York, New York, United States, 10016 | |
| United States, Pennsylvania | |
| Doylestown Hospital MRI | |
| Doylestown, Pennsylvania, United States, 18901 | |
| Doylestown Hospital | |
| Doylestown, Pennsylvania, United States, 18901 | |
| Nephrology/Hypertension Specialists | |
| Doylestown, Pennsylvania, United States, 18901 | |
| United States, Texas | |
| Renal Associates, PA | |
| San Antonio, Texas, United States, 78215 | |
| San Antonio Kidney Disease Center Physicians Group, P.L.L.C. | |
| San Antonio, Texas, United States, 78229 | |
| United States, Virginia | |
| University of Virginia Health System - Nephrology | |
| Charlottesville, Virginia, United States, 22908 | |
| University of Virginia Health System | |
| Charlottesville, Virginia, United States, 22908 | |
| United States, Washington | |
| The Polyclinic | |
| Seattle, Washington, United States, 98104 | |
| Renal Remission and Hypertension Clinic | |
| Silverdale, Washington, United States, 98383 | |
| Australia, Victoria | |
| Monash Medical Centre | |
| Clayton, Victoria, Australia, 3168 | |
| Canada, Ontario | |
| Toronto General Hospital | |
| Toronto, Ontario, Canada, M5G 2N2 | |
| Canada, Quebec | |
| Hopital du Sacre-Coeur de Montreal | |
| Montreal, Quebec, Canada, H4J 1C5 | |
| Czech Republic | |
| Klinika gerontologicka a metabolicka | |
| Hradec Kralove, Czech Republic, 500 05 | |
| Krajska nemocnice Liberec | |
| Liberec 1, Czech Republic, 460 63 | |
| Nemocnice Nove Mesto na Morave | |
| Nove Mesto na Morave, Czech Republic, 592 31 | |
| Fakultni poliklinika VFN | |
| Praha 2, Czech Republic, 128 00 | |
| Vseobecna fakultni nemocnice v Praze | |
| Praha 2, Czech Republic, 128 08 | |
| Pharmaceutical Research Associates CZ, s.r.o. | |
| Praha 7, Czech Republic, 170 00 | |
| Hungary | |
| PRA Magyarorszag Kft. Klinikai Farmakologiai Vizsgalohely | |
| Budapest, Hungary, 1077 | |
| Fovarosi Onkormanyzat Szent Imre Korhaz BSZMI Klinikai Farmakologiai Reszlege | |
| Budapest, Hungary, 1115 | |
| Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont I.sz.Belgyogyaszati Klinika | |
| Szeged, Hungary, 6720 | |
| Italy | |
| Istituti Ospitalieri di Cremona | |
| Cremona, Italy, 26100 | |
| A.O. Universitaria Ospedali Riuniti di Foggia | |
| Foggia, Italy, 71100 | |
| Korea, Republic of | |
| Seoul National University Hospital, Department of Internal Medicine | |
| Seoul, Korea, Republic of, 110-744 | |
| Samsung Medical Center/Division of Nephrology | |
| Seoul, Korea, Republic of, 135-710 | |
| Eulji General Hospital | |
| Seoul, Korea, Republic of, 139-872 | |
| Lithuania | |
| Vilnius University Hospital Santariskiu Clinic, Public Institution, Centre of Nephrology | |
| Vilnius, Lithuania, 08661 | |
| Moldova, Republic of | |
| Spitalul Clinic Republican | |
| Chisinau, Moldova, Republic of, 2025 | |
| Poland | |
| Zaklad Diagnostyki Chorob Serca, II Katedra Kardiologii | |
| Gdansk, Poland, 80-210 | |
| Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych | |
| Gdansk, Poland, 80-952 | |
| Specjalistyczny Szpital Zachodni im. Jana Pawla II w Grodzisku Mazowieckim | |
| Grodzisk Mazowiecki, Poland, 05-825 | |
| Krakowskie Centrum Medyczne NZOZ | |
| Krakow, Poland, 31-501 | |
| Klinika Nefrologii, Hipertensjologii i Chorob Wewnetrznych Katedry Chorob Wewnetrznych UWM | |
| Olsztyn, Poland, 10-561 | |
| Pracownia Echokardiografii, Oddzial Kardiologii | |
| Olsztyn, Poland, 10-561 | |
| Centrum Medyczne Aesculap | |
| Radom, Poland, 26-600 | |
| Klinika Kardiologii | |
| Szczecin, Poland, 70-111 | |
| Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych | |
| Szczecin, Poland, 70-111 | |
| Szpital Powiatowy w Wolominie | |
| Wolomin, Poland, 05-200 | |
| SPZOZ Akademicki Szpital Kliniczny im. J. Mikulicza - Radeckiego | |
| Wroclaw, Poland, 50-556 | |
| Romania | |
| Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea | |
| Oradea, jud. Bihor, Romania, 410469 | |
| Spitalul Clinic Dr. C. I. Parhon Iasi | |
| Iasi, jud. Iasi, Romania, 700503 | |
| Institutul Clinic Fundeni, Centrul de Medicina Interna-Nefrologie | |
| Bucuresti, Romania, 022328 | |
| SPITALUL CLINIC JUDETEAN DE URGENTA TIMISOARA ,Clinica de Nefrologie | |
| Timisoara, Romania, 300736 | |
| Slovakia | |
| Univerzitna nemocnica Bratislava | |
| Limbova 5, Bratislava, Slovakia, 83305 | |
| SUMMIT CLINICAL RESEARCH, s.r.o., Oddelenie internej mediciny a klinickej farmakologie | |
| Bratislava, Slovakia, 831 01 | |
| Spain | |
| Hospital Universitari de Bellvitge | |
| Hospitalet de Llobregat, Barcelona, Spain, 08907 | |
| Hospital Clinic I Provincial de Barcelona | |
| Barcelona, Spain, 08036 | |
| Sweden | |
| Sahlgrenska Universitetssjukhuset, Njurmedicin | |
| Goteborg, Sweden, 413 45 | |
| Karolinska Universitetssjukhuset Huddinge | |
| Stockholm, Sweden, 141 86 | |
| Karolinska Universitetssjukhuset Solna | |
| Stockholm, Sweden, 171 76 | |
| Switzerland | |
| Universitaetsspital Zuerich | |
| Zuerich, Switzerland, 8091 | |
| Turkey | |
| Istanbul University, Istanbul Tip Fakultesi | |
| Istanbul, Capa, Turkey, 34390 | |
| Dokuz Eylul Universitesi Hastanesi Ic Hastaliklari Anabilim Dali | |
| Izmir, Inciralti/ Narlidere, Turkey, 35340 | |
| United Kingdom | |
| Morriston Hospital | |
| Swansea, Wales, United Kingdom, SA6 6NL | |
| BHF Glasgow Cardiovascular Research Centre, University of Glasgow | |
| Glasgow, United Kingdom, G12 8TA | |
| Renal and Urology Directorate, Leicester General Hospital | |
| Leicester, United Kingdom, LE5 4PW | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT01233869 History of Changes |
| Other Study ID Numbers: | B1871019 3160A7-2211 2010-023017-65 |
| Study First Received: | October 28, 2010 |
| Results First Received: | August 26, 2015 |
| Last Updated: | February 10, 2016 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Pfizer:
|
Bosutinib Autosomal Dominant Polycystic Kidney Disease |
Additional relevant MeSH terms:
|
Kidney Diseases Polycystic Kidney Diseases Polycystic Kidney, Autosomal Dominant Urologic Diseases Kidney Diseases, Cystic |
ClinicalTrials.gov processed this record on September 30, 2016